Información del artículo
El Texto completo está disponible en PDF
References
[1.]
A. Rego-Iraeta, L.F. Pérez, B. Mantiñán, R.V. García-Mayor.
Time trends for thyroid cancer in north western Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma.
Thyroid, 19 (2009), pp. 333-340
[2.]
A. Rego-Iraeta, L.F. Pérez, B. Mantiñán, R.V. García-Mayor.
In addition to increased diagnostic activity, other enviromental factors may contribute to the rising incidence of papillary thyroid cancer.
Clin Thyroid, 21 (2009), pp. 16-18
[3.]
M. Schlumberger, C. Challeton, F. De Vathaire, J.P. Travagli, P. Gardet, J.P. Lumbroso, et al.
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
J Nucl Med, 37 (1996), pp. 598-605
[4.]
A. Ríos, J.M. Rodríguez, M.D. Balsalobre, B. Febrero, J. Tébar, P. Parrilla.
Metástasis a distancia como forma de inicio de un carcinoma folicular de tiroides.
Endocrinol Nutr, 56 (2009), pp. 213-214
[5.]
O. Gagey, C. Court, N. Ziad, M. Schlumberger.
Pelvic and spinal giant metastases from thyroid carcinomas: report of 8 cases.
Rev Chir Orthop Reparatrice Appar Mot, 87 (2001), pp. 579-584
[6.]
C.A. Benbassat, S. Mechlis-Frish, D. Hirsch.
Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer.
World J Surg, 30 (2006), pp. 1088-1095
[7.]
M.M. Muresan, P. Olivier, J. Leclère, F. Sirveaux, L. Brunaud, M. Klein, et al.
Bone metastases from differentiated thyroid carcinoma.
Endocr RelCancer, 15 (2008), pp. 37-49
[8.]
M. Shoup, A. Stojadinovic, A. Nissan, R.A. Ghossein, S. Freedman, M.F. Brennan, et al.
Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.
J Am Coll Surg, 197 (2003), pp. 191-197
[9.]
M.O. Bernier, L. Leenhardt, C. Hoang, A. Aurengo, J.Y. Mary, F. Menegaux, et al.
Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas.
J Clin Endocrinol Metab, 86 (2001), pp. 1568-1573
[10.]
C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, et al.
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
J Clin Endocrinol Metab, 91 (2006), pp. 2892-2899
[11.]
F. Pacini, F. Cetani, P. Miccoli, F. Mancusi, C. Ceccarelli, F. Lippi, et al.
Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine.
World J Surg, 18 (1994), pp. 600-604
[12.]
C.F. Eustatia-Rutten, J.A. Romijn, M.J. Guijt, G.J. Vielvoye, R. Van den Berg, L. Corssmit, et al.
Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma.
J Clin Endocrinol Metab, 88 (2003), pp. 3184-3189
[13.]
M.E. Cabanillas, S.G. Waguespack, Y. Bronstein, M.D. Williams, L. Feng, A. López, et al.
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the MD Anderson experience.
J Clin Endocrinol Metab, 95 (2010), pp. 2588-2595
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
